# Newomics, Inc.

> Newomics is a Berkeley, California biotechnology company building mass spectrometry front-end hardware for precision medicine. Spun out of Lawrence Berkeley National Laboratory, its silicon multinozzle emitter (M3) and MnESI ion source upgrade existing mass spectrometers to deliver microflow robustness with nanospray sensitivity, enabling higher-throughput, higher-sensitivity multiomics across proteomics, metabolomics, lipidomics, native MS and single-cell analysis. The company sells to pharmaceutical, academic and government labs and co-markets with major instrument vendors like Thermo Fisher Scientific.

- **Founded:** 2011
- **Headquarters:** Berkeley, California, United States
- **Founders:** Daojing Wang (Founder & CEO), Pan Mao (Co-founder)
- **Team size:** ~9 employees
- **Products:** M3 Emitter, MnESI Source, UniESI System, MEA Chip
- **Notable:** Multinozzle emitter array (MEA) technology won the 2012 R&D 100 Award at Berkeley Lab, Raised $11.8M total including a $7.9M Series B led by MSA Capital (2020), ISO 9001:2015 certified

## Products & services

- **M3 Emitter** — An award-winning multinozzle silicon microfluidic emitter chip (from the Berkeley Lab multinozzle emitter array technology) that boosts signal intensity, identification, quantification and isomer resolution for low-input samples.
- **MnESI Source** — A Microflow-nanospray Electrospray Ionization source that pairs microflow LC robustness with nanospray sensitivity; compatible with Thermo Fisher and Bruker mass spectrometers.
- **UniESI System** — An ion source with swappable nano/microflow modules for flexible multiomics workflows.
- **MEA Chip** — A microfluidic analytical chip with an on-chip LC column for integrated separation and ionization.

## Achievements

- Multinozzle emitter array (MEA) technology won the 2012 R&D 100 Award at Berkeley Lab
- Raised $11.8M total including a $7.9M Series B led by MSA Capital (2020)
- ISO 9001:2015 certified
- Co-marketing agreements with Thermo Fisher Scientific
- Platform technologies featured in peer-reviewed publications including native N-glycan analysis

## Latest updates

- **2020-12** — Closed $7.9M Series B led by MSA Capital to launch new products and grow sales and marketing.
- **2020-12** — Completed second co-marketing agreement with Thermo Fisher Scientific and launched the MnESI-MS platform for clinical diagnostics and drug discovery.

## Links

- Website: https://newomics.com
- LinkedIn: https://www.linkedin.com/company/newomics-inc-
- Twitter/X: https://twitter.com/NewomicsInc
- YouTube: https://www.youtube.com/watch?v=-bV1SeSHhPA

---

Profile page: https://yespress.io/newomics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13